Glasgow-based Mironid Secures $39.9 Million in Latest Series B Funding Round

Glasgow-based Mironid secured $39.9 million in its latest Series B, adding another data point to the FinTech funding market.

Glasgow-based Mironid Raises $39.9 million in Funding

Glasgow-based Mironid raises €39.9 million in Series B to advance rare kidney disease treatment. This is a paid press release.

Investors Behind the Funding

The round was backed by an industry-experienced management team. Capvizr tracks this investor activity alongside sector momentum, co-investor patterns, and recent comparable raises.

Company Profile and Market Context

Glasgow-based Mironid operates in FinTech. Glasgow-based Mironid's financing adds to recent private-market activity.

Strategic Use of Funds

Advance rare kidney disease treatment.

Looking Ahead

Glasgow-based Mironid raises €39.9 million in Series B to advance rare kidney disease treatment.

Source reference: original announcement/article.